Using Linked Data to Explore the Association Between Statin Medicine Adherence and Hospitalisation Following A Large Patient Co-Payment Increase (original) (raw)
Related papers
Medical Archives, 2013
B ackground: The compliance to statins in secondary prevention is very low, increasing health-care costs principally for rehospitalization. Objectives: To evaluate the cost of lack of persistence to statin therapy together with identification and cost-estimation of poor compliance. Methods: Retrospective observational study starting from administrative database analysis of statin prescription after myocardial infarction. Results: Among 463 patients enrolled, 25.1% were never treated, 70.8% received statins regularly; 14.9% received only 1-2 prescriptions (spot prescription), and 12% were occasional users. Among the 288 nonoccasional users, we found a compliance rate of 80% only in the 59.7%. The cost analysis shows that 59.787,72€ (23.4%) have been spent for patients with compliance of less than 80% (ineffective adherence). Conclusions: As the lower compliance affects the health-care costs, the identification of occasional users and spot prescriptions of the nonoccasional users, has a potential role in reducing medical expense with limited increase in costs.
Public Health Research & Practice
The proportion of individuals who reduced or ceased use of statin medications in 2005 increased by 2.1% compared with 2004, following an increase in the Pharmaceutical Benefits Scheme copayment for medications • Of those who ceased or reduced statin use, 8% and 10%, respectively, had prior heart disease, putting them at an increased risk of harms from suboptimal use of lipid-lowering therapy • General beneficiary status, and younger and healthier people were particularly at risk of ceasing or reducing statin medication • The findings provide policy makers and clinicians with new information about the impact of a large increase in the medication copayment on the use of medications by specific subgroups Research
Background: Initiation of statin therapy as primary prevention particularly in those with mildly elevated cardiovascular disease risk factors is still being debated. The 2013 ACC/AHA blood cholesterol guideline recommends initiation of statin by estimating the 10-year atherosclerotic cardiovascular disease (ASCVD) risk using the new pooled cohort risk score. This paper examines the use of the pooled cohort risk score and compares it to actual use of statins in daily clinical practice in a primary care setting. Methods: We examined the use of statins in a randomly selected sample of patients in a primary care clinic. The demographic data and cardiovascular risk parameters were captured from patient records in 1998. The pooled cohort risk score was calculated based on the parameters in 1998. The use of statins in 1998 and 2007, a 10-year interval, was recorded.
Statin usage and all-cause and disease-specific mortality in a nationwide study
Pharmacoepidemiology and Drug Safety, 2012
Context The consumption of statins (HMG-CoA reductase inhibitors) in most Western countries has increased to the extent that it may affect all-cause and disease-specific mortality. Objective To analyze the association of statin use with all-cause and disease-specific mortality utilizing nationwide databases in a record linkage study in Finland. Methods The study population included all statin users in Finland who had purchased at least one prescription between 1997 and 2005. A control population matched for age, sex, and place of residence and without statin usage was selected. The study population consisted of 336 618 pairs of individuals, and the mean length of follow-up was 4.4 years. All-cause mortality and mortality caused by coronary heart disease (CHD), stroke, other circulatory causes, cancer, unnatural causes, and suicide were analyzed. Persistence to treatment was calculated by varying adherence criteria between 20 and 80%. Results We observed association between all-cause, non-CHD and CHD and treatment with statins in statin user group. For CHD mortality, we observed a relationship between the persistence to statin treatment and a decreasing CHD mortality. For each 10% increase in adherence criteria, a 5% (2-8%) decrease in CHD mortality was observed within the range of 20% (RR 0.81, 95%CI 0.32-2.02) to 80% (RR 0.54, 95%CI 0.46-0.64). Conclusion In this nationwide study, long-term use of statins is associated with the reduction in CHD mortality.
Did Australia's COVID-19 Restrictions Impact Statin Incidence, Prevalence or Adherence?
Current Problems in Cardiology, 2023
COVID-19 restrictions may have an unintended consequence of limiting access to cardiovascular care. Australia implemented adaptive interventions (eg, telehealth consultations, digital image prescriptions, continued dispensing, medication delivery) to maintain medication access. This study investigated whether COVID-19 restrictions in different jurisdictions coincided with changes in statin incidence, prevalence and adherence. Analysis of a 10% random sample of national medication claims data from January 2018 to December 2020 was conducted across 3 Australian jurisdictions. Weekly incidence and prevalence were
The American journal of managed care, 2010
To analyze differences in the pattern of statin use among 10 consecutive yearly cohorts of new users in Finland. Retrospective cohort study based on administrative claims data. New users of statins from January 1, 1995, to December 31, 2004, were captured from a nationwide prescription register, and the pattern of statin use was observed until December 31, 2005. The association between year of statin initiation and persistence with statin therapy during the first year of statin use was modeled using Cox proportional hazards regression analysis with multivariable adjustment. The median adherence (proportion of days covered) was computed among patients who discontinued therapy during each 365-day interval since statin initiation. In total, 490,024 new users of statins were identified. In the multivariable-adjusted model, discontinuation during the first year among initiators of statin use in 1996 and 1997 was similar to that in 1995 (hazard ratio [HR], 0.99; 95% confidence interval [C...